tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Ligand Pharmaceuticals Inc

LGND
Add to Watchlist
298.667USD
-1.863-0.62%
Market hours （ET）Quotes delayed by 15 min
5.91BMarket Cap
38.92P/E TTM

Ligand Pharmaceuticals Inc

298.667
-1.863-0.62%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

LGND Financials

See Ligand Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Ligand Pharmaceuticals Inc Earnings Date

Latest Release
Aug 6, 2026
EPS / Forecast
--/1.87
Revenue / Forecast
--/61.28M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
215.01M
28.65%
EPS(YoY)
6.13
2881.81%
Analyst Rating
BUY
2026/07/27
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
69.66%-0.67
234.71%2.21
1638.35%5.99
108.71%0.25
-145.54%-2.21
-273.88%-1.64
34.12%-0.39
-2272.37%-2.88
97.59%4.86
191.02%0.94
---0.59
--0.13
--2.46
---1.04
---1.23
----
----
----
----
----
Revenue
14.09%51.72M
39.37%59.67M
122.85%115.46M
14.68%47.63M
46.34%45.33M
52.35%42.81M
57.64%51.81M
57.52%41.53M
-29.56%30.98M
3.90%28.10M
-44.50%32.87M
-54.08%26.37M
20.44%43.98M
-62.68%27.05M
-8.66%59.22M
-32.19%57.42M
-33.79%36.52M
3.55%72.47M
54.93%64.83M
104.43%84.67M
Net Profit
68.56%-13.35M
244.06%44.78M
1735.15%117.27M
109.34%4.85M
-149.28%-42.45M
-270.93%-31.09M
30.19%-7.17M
-2366.86%-51.91M
105.34%86.14M
204.02%18.19M
-2642.82%-10.27M
355.87%2.29M
372.66%41.95M
-222.84%-17.48M
-97.06%404.00K
-102.91%-895.00K
-184.97%-15.38M
-194.01%-5.42M
304.79%13.72M
39.12%30.73M
Net Margin
72.45%-25.80%
203.36%75.06%
833.76%101.57%
108.14%10.18%
-133.68%-93.64%
-212.19%-72.62%
55.71%-13.84%
-1539.12%-124.99%
180.39%278.07%
64.25%64.72%
---31.26%
--8.69%
--99.17%
--39.40%
--3.06%
----
----
----
----
----
Gross Margin
9.74%78.02%
9.90%81.42%
13.06%89.70%
4.70%76.56%
10.61%71.09%
14.88%74.08%
23.32%79.33%
19.32%73.12%
-10.90%64.27%
221.14%64.49%
--64.33%
--61.28%
--72.13%
--20.08%
--60.98%
----
----
----
----
----
Debt to assets ratio
1100607.92%29.17%
368849.42%28.59%
1201759.36%30.17%
82.01%0.00%
703.03%0.00%
134.85%0.01%
--0.00%
--0.00%
-100.00%0.00%
-99.97%0.00%
--0.00%
--0.00%
--9.47%
--10.06%
--7.30%
----
----
----
----
----
Income Statement
Revenue
14.09%51.72M
39.37%59.67M
122.85%115.46M
14.68%47.63M
46.34%45.33M
52.35%42.81M
57.64%51.81M
57.52%41.53M
-29.56%30.98M
3.90%28.10M
-44.50%32.87M
-54.08%26.37M
20.44%43.98M
-62.68%27.05M
-8.66%59.22M
-32.19%57.42M
-33.79%36.52M
3.55%72.47M
54.93%64.83M
104.43%84.67M
Operating profit
147.38%17.37M
1087.91%20.04M
-90.63%1.03M
31.51%9.72M
-1326.87%-36.66M
150.24%1.69M
1044.72%10.96M
472.72%7.39M
-78.97%2.99M
-127.58%-3.36M
-92.25%957.00K
-322.81%-1.98M
565.96%14.21M
-4.38%12.18M
-21.42%12.34M
-101.03%-469.00K
-54.76%2.13M
315.68%12.73M
319.16%15.71M
544.21%45.74M
Net Profit
68.56%-13.35M
244.06%44.78M
1735.15%117.27M
109.34%4.85M
-149.28%-42.45M
-270.93%-31.09M
30.19%-7.17M
-2366.86%-51.91M
105.34%86.14M
204.02%18.19M
-2642.82%-10.27M
355.87%2.29M
372.66%41.95M
-222.84%-17.48M
-97.06%404.00K
-102.91%-895.00K
-184.97%-15.38M
-194.01%-5.42M
304.79%13.72M
39.12%30.73M
Balance Sheet
Current assets
179.78%865.41M
151.02%832.27M
143.68%753.92M
13.03%352.94M
-16.15%309.32M
39.65%331.56M
21.81%309.39M
12.85%312.26M
12.41%368.91M
-9.93%237.43M
15.23%253.99M
13.51%276.71M
18.88%328.19M
-43.28%263.60M
-48.98%220.43M
-40.67%243.78M
-36.89%276.07M
-7.15%464.75M
-49.63%432.08M
-52.42%410.90M
Total current liabilities
-30.70%40.67M
0.90%37.45M
23.28%30.54M
248.69%64.73M
229.35%58.68M
121.14%37.11M
57.51%24.77M
-36.83%18.57M
-81.99%17.82M
-83.02%16.78M
-88.37%15.73M
-82.49%29.39M
132.35%98.93M
137.15%98.81M
272.60%135.24M
219.74%167.85M
-55.56%42.58M
-58.38%41.66M
-14.19%36.30M
79.39%52.50M
Total assets
69.21%1.53B
65.71%1.56B
54.66%1.48B
9.49%948.60M
-0.92%905.43M
19.63%941.77M
24.13%954.87M
14.29%866.40M
12.67%913.87M
3.22%787.22M
-26.78%769.23M
-29.56%758.11M
-26.61%811.08M
-41.22%762.67M
-17.51%1.05B
-14.33%1.08B
-14.67%1.11B
-4.75%1.30B
2.10%1.27B
1.07%1.26B
Total liabilities
386.60%534.78M
388.10%543.42M
363.20%526.60M
31.65%120.08M
2.38%109.90M
29.00%111.33M
12.20%113.69M
-2.15%91.21M
-34.85%107.35M
-47.75%86.30M
-56.75%101.33M
-65.97%93.21M
-47.19%164.76M
-65.33%165.18M
-49.24%234.31M
-41.69%273.92M
-43.20%311.99M
-27.01%476.43M
-16.02%461.59M
-14.27%469.77M
Total equity
25.37%997.32M
22.49%1.02B
12.96%950.17M
6.88%828.53M
-1.36%795.53M
18.48%830.44M
25.94%841.18M
16.59%775.20M
24.79%806.52M
17.31%700.91M
-18.18%667.90M
-17.13%664.89M
-18.52%646.32M
-27.24%597.49M
0.52%816.30M
2.01%802.37M
6.35%793.19M
15.73%821.16M
16.37%812.07M
13.17%786.52M
Cash Flow Statement
Net operating income
291.36%48.69M
61.27%45.91M
-64.17%13.09M
18.66%15.80M
-235.84%-25.45M
253.02%28.47M
377.77%36.53M
16336.59%13.31M
-44.82%18.73M
-84.92%8.06M
-62.68%7.65M
-100.69%-82.00K
-34.73%33.95M
93.44%53.47M
2.32%20.49M
-41.71%11.88M
383.64%52.01M
5047.49%27.64M
57.12%20.02M
-16.43%20.38M
Net investment
-2027.81%-94.35M
53.13%-18.10M
-659.98%-353.44M
80.52%-10.67M
229.64%4.89M
-275.56%-38.62M
-138.46%-46.51M
-824.71%-54.76M
-135.79%-3.77M
-41.19%-10.28M
-201.71%-19.50M
-80.04%7.56M
-90.74%10.55M
79.60%-7.28M
205.26%19.18M
95.73%37.85M
74.89%113.88M
90.66%-35.71M
-105.49%-18.22M
172.27%19.34M
Net financing
-197.72%-14.13M
-59.14%8.33M
643.73%409.64M
57.99%14.99M
-138.97%-4.75M
283.59%20.39M
1584.40%55.08M
114.01%9.49M
1671.87%12.18M
200.32%5.32M
108.01%3.27M
-13.99%-67.76M
99.55%-775.00K
-227.23%-5.30M
-10504.94%-40.83M
-19.11%-59.44M
-85.98%-170.42M
115.13%4.16M
89.61%-385.00K
-998000.00%-49.91M

FAQs

What is the total revenue of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 215.01M, with a year-on-year change of 167.13M.

What are the current assets of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its current assets were 832.27M, with a year-on-year change of 151.02.

What are the total assets of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its total assets of Ligand Pharmaceuticals Inc were 1.56B, with a year-on-year change of 65.71.

What are the total liabilities of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Ligand Pharmaceuticals Inc were 543.42M, with a year-on-year change of 388.10.

What is the total equity of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its total equity of Ligand Pharmaceuticals Inc was 1.02B, with a year-on-year change of 22.49.

What is the net operating income of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Ligand Pharmaceuticals Inc was -1.27M, with a year-on-year change of -105.53.

What is the net investment of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its net investment of Ligand Pharmaceuticals Inc was -377.32M, with a year-on-year change of -162.64.

What is the net financing of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its net financing of Ligand Pharmaceuticals Inc was 428.22M, with a year-on-year change of 340.83.

What is the Earnings Per Share (EPS) of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 6.13, with a year-on-year change of 2881.81.

What is the net income of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its net income was 124.45M, with a year-on-year change of 3186.63.

What is the net margin of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 57.88, with a year-on-year change of 2499.27.

What is the gross margin of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 78.02, with a year-on-year change of 5.93.

What is the debt-to-asset ratio of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 28.59, with a year-on-year change of 368849.42.

What is the Return on Equity (ROE) of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was 13.47, with a year-on-year change of 2658.23.

What is the Return on Assets (ROA) of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 9.95, with a year-on-year change of 2232.65.

What is the operating profit of Ligand Pharmaceuticals Inc?

According to Ligand Pharmaceuticals Inc's FY2025 earnings report, its operating profit was -1.27M, with a year-on-year change of -105.53.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy